Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Polyrizon Ltd.

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
From Polyrizon Ltd.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.